The National Health Insurance Service was found to have restarted reimbursement discussions for the obstructive hypertrophic cardiomyopathy treatment Camzyos (mavacamten, BMS).

BMS and the NHIS entered into drug price negotiations for Camzyos in August but failed to reach an agreement within the 60-day deadline. However, the deadline has been extended, and it is expected that the company may be able to list the drug for reimbursement as early as next month. In particular, there are opinions that the criticisms made during the NA audit may have accelerated the drug’s reimbursement discussions.

Lorviqua, whose reimbursement progress was also criticized during the NA Audit, may likely ski